THERAPY DOSSIER · th-7e3a244e6e6a

JSK (Ji-Sui-Kang) herbal formulation

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Spinal cord injury
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 23760224 ↗2013Reported benefit

Effects of a novel herbal formulation JSK on acute spinal cord injury in rats.

RatSpinal cord injuryContusionWistarFemalen = 12 for behavioural assessment, 6 for histology and immunoch…Oral gavageFirst dose 24 h after injury

Model: Acute contusion spinal cord injury produced with a New York University impactor

JSK improved locomotor function (n = 12, p < 0.05), reduced tissue damage (p < 0.01, n = 6) and preserved axons and myelin, with increased neuroglobin, vascular endothelial growth factor and growth-associated protein 43 and reduced caspase 3, cyclooxygenase-2, RhoA and fibrinogen

Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…